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Background: Lysosomal storage disorders (LSDs), are a heterogeneous group of rare disorders caused by defects in
genes encoding for proteins involved in the lysosomal degradation of macromolecules. They occur at a frequency
of about 1 in 5,000 live births, though recent neonatal screening suggests a higher incidence. New treatment
options for LSDs demand a rapid, early diagnosis of LSDs if maximal clinical benefit is to be achieved.
Methods: Here, we describe a novel, highly specific and sensitive biomarker for Niemann-Pick Type C disease type
1 (NPC1), lyso-sphingomyelin-509. We cross-validate this biomarker with cholestane-3β,5α,6β-triol and relative
lysosomal volume. The primary cohort for establishment of the biomarker contained 135 NPC1 patients, 66 NPC1
carriers, 241 patients with other LSDs and 46 healthy controls.
Results: With a sensitivity of 100.0% and specificity of 91.0% a cut-off of 1.4 ng/ml was established. Comparison
with cholestane-3β,5α,6β-triol and relative acidic compartment volume measurements were carried out with a
subset of 125 subjects. Both cholestane-3β,5α,6β-triol and lyso-Sphingomyelin-509 were sufficient in establishing
the diagnosis of NPC1 and correlated with disease severity.
Conclusion: In summary, we have established a new biomarker for the diagnosis of NPC1, and further studies will
be conducted to assess correlation to disease progress and monitoring treatment.
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Lysosomal storage disorders (LSDs) are a group of over
70 different inborn errors of metabolism with a com-
bined incidence around 1 in 5,000 live births [1]. Symp-
toms depend on tissue distribution and function of the
accumulating substrates [2]. Niemann-Pick Type C dis-
ease (NPC) is an autosomal-recessive LSD, that is re-
ported to affect 1:120,000 live births [3], though the
relative frequency in at-risk cohorts such as patients
with neurologic and psychiatric symptoms, is reported
to be as high as 1.2% [4]. In 95% of cases NPC is caused
by mutations in the NPC1 gene (OMIM: *607623), only* Correspondence: arndt.rolfs@med.uni-rostock.de
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creativecommons.org/publicdomain/zero/1.0/in 5% of cases have mutations in the NPC2 gene been
reported (OMIM: *601015). Currently, Miglustat is the
only EMEA-approved drug for the treatment of NPC
[5,6], though novel approaches such as cyclodextrin [7]
and histone-deacetylase inhibitors [8] are being investi-
gated. Despite clinical evaluation of patients new clinical
studies will also require assessment of independent, ob-
jective surrogate parameters to evaluate disease progres-
sion and response to treatment. In addition to the
classical Filipin staining test, which is not always conclu-
sive in patients with NPC [9], two biomarkers for NPC
have been reported to date, oxysterols [10] and measure-
ment of intracellular acidic compartment volume (mean
equivalent of fluorescence - MEFL/LysoTracker) [11].
While oxysterols facilitate the primary diagnosis of NPC,
MEFL is mainly useful in assessing the follow-up and
treatment response of patients.icle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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marker for NPC1 and cross-validate our findings with
published cholestane-3β,5α,6β-triol and MEFL data ana-
lyzing the same plasma data [11]. As a first step we
screened ten NPC1 patients and 10 age- and gender-
matched healthy controls utilizing HPLC and tandem
mass spectrometry and carefully assessed differences in
mass spectra. This resulted in the detection of lyso-
sphingomyelin-509 (lyso-SM-509) as a potential biomarker
for NPC. In the following step, we screened 135 NPC1 pa-
tients, 66 NPC1 carriers, 241 patients with other LSDs
and 46 healthy controls for lyso-SM-509. The structure is
very similar to lyso-sphingomyelin (lyso-SM), the chemical
formula being (C24H49N2O7P), though so far we were not
able to elucidate the exact structure of lyso-SM-509. In
keeping with this finding, lyso-SM-509 is also highly ele-
vated in patients with NP-A/B, though the disease is easier
to diagnose due to availability of enzyme activity assays
for sphingomyelinase.
In a second line assessment we compared lyso-SM-509
measurements with those published for cholestane-3β,
5α,6β-triol and MEFL. Here, we report on the result of the
establishment of lyso-SM-509 as a biomarker and the
cross-validation with the previously published biomarkers.
Methods
Patients and blood samples
Blood samples were obtained from patients enrolled in the
“Biomarker for Niemann-Pick Type C Disease (BioNPC)”
trial (ClinicalTrials.gov identifier: NCT01306604) and
underwent biochemical analysis or genetic testing for
verification of a suspected metabolic disease by the
Albrecht-Kossel-Institute for Neuroregeneration (AKos).
Additionally, blood plasma samples collected in the scope
of the investigation of relative acidic compartment vol-
ume in NPC have been analysed for retrospectively for
lyso-sphingomyelin-509 levels [11].
Genetic analysis, Oxysterol and LysoTracker measurements
Standard analysis of the NPC1 gene was performed ac-
cording to standard protocols [12]. All measurements
for cholestane-3β,5α,6β-triol and LysoTracker have been
performed previously [11].
Identification of lyso-sphingomyelin-509 as a biomarker
for NPC
Screening for potential biomarkers was carried out using
HPLC-MS/MS of blood plasma samples of 10 healthy
subjects and 10 NPC1 patients with accurate mass MS-
systems (Orbitrap XL) and tandem MS systems. Differ-
ences between NPC1 patients and healthy controls were
carefully assessed with regards to substances strongly in-
creased only in patients. Molecular weight and structure
of such substances were determined carefully. Peaks wereidentified by accurate mass MS-system and measured by
tandem MS/MS systems using already known internal
standards as reference. After validating the robustness of
lyso-SM-509, measurements in healthy controls, NPC1
carriers, NPC1 patients and in patients with other LSDs
ensued (For details see Additional file 1: Figure S1 and S2).
Chemical formula determination was done on an LTQ
Orbitrap XL, parent ion as well as fragment ions were de-
termined with accurate mass and high resolution leading
to the chemical formula described. Purification steps were
performed in order to receive larger and purer compound
(SPE and liquid-liquid extraction steps-for purification
only) to gain higher concentrated compound for HPLC
determination and infusion experiments. Sodium aduct
ions as well as negatively charged ions of the substance
had also been determined and studied more in depth on a
Q/TOF system. Stress tests of the substance in plasma
had been performed, it appears that the substance is stable
in plasma over several hours at room temperature, fur-
thermore strongly acidic or alkaline conditions did not
show significant degradation. Also several freeze/thaw cy-
cles in human plasma showed stability of the compound.Method for determination of free lyso-sphingomyelin and
lyso-sphingomyelin-509 in plasma
50 μL of the sample were mixed with 100 μL of Internal
Standard (lyso-Gb2 (Matreya LLC, USA)) working solu-
tion (in EtOH) and were then mixed subsequently using
a DVX-2500 Multi-tube vortex device at 2500 rpm for
about 30 seconds. After centrifugation at 4000 rpm for
2 minutes the clear supernatant was transferred into
auto-sampler vials and injected into the HPLC-MS/MS
system. Mobile phase used for gradient elution was
50 mM formic acid in water and 50 mM formic acid in
acetonitrile/acetone (1/1, v/v). HPLC flow was set at
0.9 mL/min on an ACE 3 C8 column (50 × 2.1 mm) at
60°C, the injection volume used was 5 μL. Retention
time for the analytes were approximately 3.2 minutes for
lyso-SM and 3.6 minutes for lyso-SM-509, and for the
internal standard (lyso-Gb2 (Matreya LLC, USA)) ap-
proximately 3.2 minutes. Lyso-Gb2 was checked in
regards to native concentrations in plasma and was
found to be at very low levels only, a sufficient amount
was added therefore during sample preparation. The
MS/MS system used was an API 4000 using electrospray
ionization in MRM mode in positive mode at 500°C for
determination of free Lyso-Sphingomyelin in plasma.
Quadrupole resolution was set at unit /unit, MRM tran-
sitions used were 465→ 184 m/z for the analyte, 509→
184 m/z for 509, and 624→ 282 for the internal stand-
ard. Calibration was done from 2 ng/mL to 200 ng/mL
in aqueous/methanolic solution; QC samples were spiked
in plasma at levels of 15 and 150 ng/mL.
Figure 1 Chemical structure of Lyso-Sphingomyelin-509. This substance was analysed by HPLC-MS/MS with high sensitivity and specificity of
diagnosing NPC. The precise structure of lyso-SM-509 has not yet been elucidated.
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Statistics for lyso-sphingomyelin-509
Data were aggregated by taking the first measured value
according to genotype (NPC1 patients, NPC1 carriers,
NP- A/B patients, P-A/B carriers and healthy controls).
Data is given in median and interquartile range where
indicated. In order to analyze the diagnostic value of
lyso-sphingomyelin-509 a receiver operating characteris-
tic (ROC) curve was employed and the area under the
curve (AUC) with 95%CI was calculated. Descriptive
statistics and ROC curve analysis were done using SPSS
Release Version 22 (© SPSS, Inc., 2013, Chicago, IL,
www.spss.com).
For comparison with MEFL and cholestane-3β,5α,6β-triol
data
Logistic regression models were fitted to compare pro-
portions, Wilcoxon-Mann-Whitney and Kruskal-Wallis
tests were used to compare medians, and ANOVA was
used to compare means where appropriate. Linear re-
gression models were fitted with maximum likelihood. A
locally adaptive super smoother was used to extract the
data structure without a regression model [13]. These
calculations were performed in the R language andTable 1 Characteristics of investigated populations
Cohort Individuals (n) Measurements (n) Age (first
(median,
NPC1 patients 110 241 13 (4-20)
(n = 67)
NPC1 carriers 63 94 46 (25-54)
(n = 20)
NP-A/B patients 21 21 9 (1-15)
(n = 14)
NP-A/B carriers 5 5 7 (min-ma
(n = 3)
Healthy controls 43 47 41 (20-50)
(n = 12)
Individual level data on age and gender was not documented for all samples. Ageenvironment for statistical computing (version 2.14.2;
http://www.R-project.org). Graphs with error bars repre-
sent mean ± SD. A p-value smaller than 0.05 was consid-
ered significant.
Study approval
The protocol of the BioNPC trial has been approved by
the Research Ethics Committee of the University Rostock
(ClinicalTrials.gov identifier: NCT01306604). Patients
undergoing therapy were treated according to stand-
ard protocols. Written informed consent was obtained
from all participants or their legal guardians.
Results and discussion
Establishment of lyso-sphingomyelin-509 as a biomarker
for NPC and characterization of the study cohort
The recently emerging novel treatment approaches for
treating NPC including cyclodextrin [7], HSP70 and
HDAC inhibitors [8] strengthen the need for early diag-
nosis and monitoring of disease progression. Biomarkers
for LSDs have been investigated for some time to facili-
tate diagnosis and monitoring response to therapy. In,
1989 Rosengren and colleagues investigated the glyco-
sphingolipid pattern in late infantile metachromaticvalue) Males (n) Females (n)
IQR, number of cases) Age (median, IQR) Age (median, IQR)
33 33
13 (4-19) 12 (5-23)
8 12
48 (27-56) 45 (14-53)
10 4
7 (1-15) 11 (3-47)
x: 2-35) 1 2
7 yrs Med.: 19
3 9
51 (min-max: 4-71)) 38 (21-46)
and gender are stated only where available.
Figure 2 Levels of lyso-SM-509 in patients with NPC1 (n = 110), NP-A/B (n = 21), as well as healthy controls (n = 43) and NPC1 carriers (n = 63)
and NP-A/B carriers (n = 5). (A) Lyso-SM-509 allows distinguishing between healthy controls and patients with NPC1. Notably, the biomarker levels
are for NP-A/B patients were 3.55-times higher (29.4 ng/ml (IQR: 14.8-40.0). Notably, only in two cases lyso-SM-509 levels above 2.5 ng/ml can be
detected in a carrier of a NPC1 mutation and in none of the healthy controls. (B) Levels of lyso-SM-509 in NPC1 by age. Note that Lyso-SM-509 is
higher in younger NPC1 patients (ρ = -0.519, p < 0.001), reflecting the severity of early onset disease as shown by Te Vruchte and colleagues (11).
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tified in MLD and normal brain tissue subsequently, the
authors arguing for a de novo synthesis of lysoglycosphin-
golipids from sphingosine and arrive at the conclusion
that they do not play a role in disease pathology [14].
Since then the perception of lysoglycosphingolipids
has changed dramatically. For example several lysosphin-
golipid biomarkers having been established recently, e.g.
lyso-Globotriaosylceramide (lyso-Gb3) in Fabry disease
[15], Glucosylsphingosine (lyso-GL-1) in Gaucher disease
[16], Galactosylsphingosine (Psychosine) in Krabbe disease
[17,18] and lyso-sphingomyelin in Niemann-Pick B pa-
tients [19].
Here, we investigated a potential biomarker for NPC1,
lyso-SM-509. For the establishment of a biomarker for
NPC1 the plasma samples of 10 NPC1 patients and 10
healthy controls were analyzed by tandem mass spectrom-
etry as described in the Material and Methods section.
After initial testing, lyso-SM-509 (Figure 1, for additional
information see Supplement) was determined as an inter-
esting target for the primary diagnosis of NPC1. Though
we have established C24H49N2O7P as the molecular for-
mula for lyso-SM-509 (lyso-SM with the addition ofTable 2 Medians and interquartile ranges for lyso-SM-509
in ng/ml for all investigated sub-cohorts
n Lyso-SM-509 in ng/ml
NPC1 patients 110 6.7 (3.4-10.3)
NPC1 carriers 63 0.4 (0.2-0.9)
NP- A/B patients 21 29.4 (14.8-40.0)
NP- A/B carrier 5 0.09 (0.04-0.16)
Healthy controls 43 0.04 (0.03-0.06)carbon dioxide, the compound was dubbed for the mass
weight examined, Figure 1), the exact structure is still sub-
ject of investigation. Current results suggest that the car-
bon dioxide is most likely located at the amino group of
the lyso-SM (data not shown). A calculation of peak area
ratio to internal standard was used for lyso-SM-509. To
date, the mechanism by which lysoglycosphingolipids arise
has not been elucidated, the most prominent hypothesis,
also for lyso-Gb3 and lyso-GL1, being the deacylation of
the corresponding glycosphingolipid [15,16,20].
Overall, 242 subjects with originally 408 measurement
points were analyzed, the main cohorts were (1) NPC1
patients (n = 110, median age 13 years, (2) NPC1 carriers
(n = 63, median age: 46, (3) NP-A/B patients (n = 21, me-
dian age: 9, (4) NP-A/B carriers (n = 5, median age: 7),
and (5) healthy controls (n = 43, median age: 41 (for de-
tails see Table 1). For NPC1 patients a median lyso-SM-
509 value of 6.7 ng/ml was measured, NP-A/B patients
displayed about 4-times higher values (29.4 ng/ml), while
neither NPC1 carriers, NP-A/B carriers, nor healthy con-
trols displayed elevated values (for details see Figure 2A, B
and Table 2). Of note, in two instances NPC1 carriersTable 3 Sensitivity, specificity and accuracy of lyso-SM-509
in NPC1 patients
Lyso-SM-509
NPC1 patients (n) 110 (221)




AUC and 95%CI in ROC Analysis 0.99 (0.98-1.00)
Figure 3 Comparison of Lyso-SM-509, cholestane-3β,5α,6β-triol and MEFL. (A) Boxplot of lyso-SM-509 by genotype, (B) boxplot of cholestane-
3β,5α,6β-triol by genotype, (C) boxplot of MEFL (LysoTracker) by genotype. Both lyso-SM-509 and cholestane-3β,5α,6β-triol facilitate the distinction of
NPC patients from healthy controls.
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ents of genetically confirmed NPC1 patients and both
underwent genotyping confirming their carrier status. In
summary, a cut-point of 1.4 ng/ml for lyso-SM-509 was
determined to distinguish NPC1 patients from NP-A/B
patients, NPC1 carriers, NP-A/B carriers and healthy con-
trols (sensitivity: 100.0%, specificity: 91.0%, ROC-curve
analysis: Area under the curve (AUC): 0.99, 95% CI: 0.98-
1.00) (Table 3). We conclude that lyso-SM-509 is useful in
determining the primary diagnosis of NPC1.Figure 4 Comparison of MEFL (LysoTracker) (log scale) and lyso-SM-509 (li
NPC1 patients (ρ =0.432, p < 0.001). The Red line is a linear model.Relationship to MEFL and cholestane3β,5α,6β‐triol
For NPC1, two other biomarkers have already been estab-
lished – non-enzymatically generated Oxysterols and the
LysoTracker (by assessing MEFL as a measure of relative
lysosomal volume) [10,11]. In the second part of our
paper, the newly established lyso-SM-509 has been com-
pared to both in the same plasma samples. Even though,
two different biomarkers have been established and can be
utilized for different aspects of the disease (Oxysterols for
primary diagnosis by measurement of either Cholestane-near scale). Levels of lyso-SM-509 significantly correlate with MEFL in
Figure 5 Cholestane-3β,5α,6β-triol vs lyso-SM-509 (log-log scale) by genotype. Lyso-SM-509 and cholestane-3β,5α,6β-triol correlate very well by
genotype (Healthy controls, NPC1 carriers and NPC1 patients; ρ = 0.675, p <0.001); blue line is a super smoother.
Giese et al. Orphanet Journal of Rare Diseases  (2015) 10:78 Page 6 of 83β,5α,6β-triol or 7-ketocholesterol, which allows for dis-
crimination between controls and NPC1 subjects [10]
vs. MEFL for monitoring of disease progression and
treatment response, which has been assessed in a 5-year
prospective study [11]), an ideal biomarker for the pri-
mary diagnosis, monitoring of disease progression and
treatment response has not yet been established. Lyso-
sphingomyelin-509 as a biomarker for NPC adds dis-
criminatory power to identify and will further facilitateFigure 6 Linear Modelling for all NPC patients. Linear modelling was perfo
cholestane-3β,5α,6β-triol (C) were available. Each patient contributes only o
ASIS (p = 0.003 (A), p = 0.039 (B), and p < 0.001 (C). The red lines corresponearly disease diagnosis. In fact, many diseases – even
common diseases such as myocardial infarction – in-
volve several biomarkers being used for primary diagno-
sis and follow-up. Therefore, our findings significantly
contribute to the current literature on diagnosing NPC
by adding a new biomarker.
In order to investigate the relationship of lyso-
sphingomyelin-509 to MEFL and cholestane-3β,5α,6β-
triol (Oxysterols), we measured its values in 240 samplesrmed for all NPC patients were ASIS, Lyso-SM-509 (A), MEFL (B) and
ne measurement. All three biomarkers significantly correlated with
d to the linear models fitted.
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and healthy controls) that were previously collected and
analyzed by FM Platt and colleagues in the scope of a 5-
year international prospective study investigating lysosomal
volume in B cells from NPC patients [11]. Data for this
subcohort of samples are summarized in Figure 3A-C.
Levels of lyso-SM-509 correlate significantly with MEFL in
NPC1 patients; ρ denotes Spearman’s correlation coefficient
(Figure 4, ρ = 0.432 p < 0.001). In addition, lyso-SM-509
levels correlate very well with cholestane-3β,5α,6β-triol
(ρ = 0.921, p < 0.001) (Figure 5) that had been measured
in the same samples and the values previously published
[10], samples overlapping with controls (lyso-SM-509 <
2.5 ng/ml) were excluded for the analysis. Taken together,
lyso-SM-509 correlated well with both cholestane-3β,5α,
6β-triol and MEFL, though lyso-SM-509 and cholestane-
3β,5α,6β-triol were very highly correlated, suggesting
they may be generated at least in part by the same
process. In line with this, the LysoTracker assay was
found to be semi-independent of both biochemical
markers and combining the MEFL with either one adding
discriminatory power to the analysis.
Correlation of biomarkers with severity scores
A randomly selected subgroup of 73 samples with mea-
surements from 36 NPC1 patients for cholestane-3β,
5α,6β-triol and lyso-SM-509 (median age: 12.76 (IQR:
9.83-17.28)) and MEFL with 57 measurements in 30 pa-
tients (median age: 13.00 (IQR: 10.38-18.49)) were ana-
lyzed for correlations with the total severity score of the
patients (excluding hearing). In agreement with previous
studies on the cholestane-3β,5α,6β-triol and MEFL there
were no significant correlations with any of these
biomarkers (data not shown) [10,11]. We also found no
significant correlation between lyso-SM-509 and total se-
verity score (ρ = 0.031, p = 0.794). However, as NPC1 is a
progressive neurodegenerative disorder, and patients
continue to progress over a number of years the annual
severity increment score (ASIS) [11] was calculated by
dividing the total severity score by age to determine rela-
tive rate of disease progression. As in the original NPC
cohort study carried out by Frances Platt and colleagues
[11], hearing was excluded since it was not measured in
all centers. Lyso-SM-509 was significantly correlated to
ASIS (slope p = 0.003), as were cholestane-3β,5α,6β-triol
(slope p < 0.001) and MEFL (slope p = 0.039) (Figure 6).
Analysis of the effect of therapy (miglustat treated vs un-
treated patients) was underpowered due to low numbers
of untreated patients (n- = 21) so a larger study will be
needed to address this.
Conclusion
In summary, we have established a novel, sensitive and
specific biomarker for the primary diagnosis of NPC1.The major advantage of lyso-SM-509 is that it is quick
and easy to measure and standardize. As a consequence,
lyso-SM-509 is definitely a useful biomarker for simple
diagnostic in blood plasma, future investigations will
analyze the sensitivity and specificity of lyso-SM-509 on
dried blood spot samples, which would further simplify
the diagnostic process.
Additional file
Additional file 1: Figure S1. Chromatogram of lyso-SM-509 (top
chromatogram) and the internal standard (bottom) in human control
plasma. There is almost no lyso-SM-509 detectable in the control sample.
Figure S2. Chromatogram of lyso-SM-509 (top chromatogram) and
internal standard (bottom) in NPC1 patient sample at a high concentration.
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